Business Context and Reporting Period
Revolution Medicines, Inc. (RVMD), a Delaware corporation, filed this Form 8-K on March 18, 2020. The filing addresses Item 5.02 regarding the departure of directors or principal officers, election of directors, appointment of certain officers, and compensatory arrangements. Specifically, it discloses the approval of bonus payments to named executive officers for performance during the year ended December 31, 2019.
Key Financial Metrics
This filing does not report company-wide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation updates.
| Executive Officer | 2019 Total Compensation | 2019 Non-Equity Incentive Plan Compensation |
|---|---|---|
| Mark A. Goldsmith, M.D., Ph.D. (CEO) | $4,576,254 | $260,980 |
| Steve Kelsey, M.D. (President, R&D) | $1,895,403 | $170,800 |
| Margaret Horn, J.D. (COO & General Counsel) | $2,215,112 | $166,150 |
Material Changes Versus Prior Period
The filing updates the Summary Compensation Table previously included in the Company's Registration Statement on Form S-1. The "Non-equity incentive plan compensation" and "Total" columns for 2019 have been revised to reflect bonus amounts that were not determined at the time the Registration Statement became effective. No other compensation amounts have changed.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future business performance. It notes that the reported stock option award values represent the aggregate grant date fair value computed in accordance with FASB ASC Topic 718. Executives will only realize compensation from these options if the trading price of the common stock exceeds the exercise price.
Key Facts for Investor Verification
- The bonus payments disclosed were approved on March 18, 2020, for the 2019 fiscal year.
- These specific bonus amounts were omitted from the original Form S-1 Registration Statement because they were undetermined at the time of effectiveness.
- Total 2019 compensation for the CEO increased significantly due to the inclusion of the $260,980 non-equity incentive bonus.
- The filing does not provide updated financial statements or operational metrics for the company.